Meetings

Vigorous physical activity promotes lung growth in children, but these benefits are reduced by ozone pollution, according to new research presented at the ATS 2026 International Conference. The findings suggest that the health benefits of exercising at levels recommended by the World Health Organization may be limited by environmental conditions.

A joint results conference of nine projects from the Transformative Change Cluster will bring together around 150 participants from science and policy on 4–5 June 2026 at Comet Louise, Brussels.

The International Society for Stem Cell Research (ISSCR) today announced that the ISSCR 2027 Annual Meeting is coming back to San Francisco, USA, 15-18 June 2027. Recognized as the premier international forum for stem cell science, the gathering will recognize 25 years of discovery, collaboration, and progress in stem cell science and gather the people, ideas, and work that will shape the next quarter century.

Tirzepatide GLP-1 medication is known to improve sleep apnea for people with both obstructive sleep apnea (OSA) and obesity, but not all patients benefit equally

A large new study presented at the 2026 ATS International Conference shows that patients treated for COPD or pneumonia experience worse outcomes across several important measures when they are treated at hospitals that have been acquired by private equity firms.

The drug tezepelumab was shown to significantly reduce exacerbations in people with severe asthma in clinical trials. Now, a new study presented at the 2026 ATS International Conference shows that it is also safe and effective in real-world patients. “Tezepelumab in Real-World U.S. Patients with Severe Asthma Across Phenotypes and Underrepresented Populations: The Phase 4 PASSAGE Study” will be published in the American Journal of Respiratory and Critical Care Medicine online on May 18.

A once-nightly oral pill helped control obstructive sleep apnea in a large, phase 3 clinical trial presented at the 2026 ATS International Conference. The drug, called AD109, is the first therapy to treat OSA by addressing its underlying mechanisms and targeting the neuromuscular causes of airway collapse. “Aroxybutynin and Atomoxetine (AD109) for Obstructive Sleep Apnea: A Randomized Phase 3 Trial” will be published in the American Journal of Respiratory and Critical Care Medicine.

New research presented at the 2026 ATS International Conference shows that pulmonary rehabilitation (PR) significantly improves functioning and quality of life in children with chronic respiratory conditions, regardless of whether lung function itself improves.

The impacts of tuberculosis (TB) are usually discussed in terms of public health and human suffering. Now, new research presented at the 2026 ATS International Conference shows that TB is also driving a massive global economic crisis.

The New York City Housing Authority developed Mold Busters, a mold-removal program, in response to a 2013 class-action lawsuit filed by residents suffering from asthma due to mold in their apartments. New research presented at the ATS 2026 International Conference shows that the program results in nearly 2,800 fewer asthma-related emergency department visits annually.